Compare Fubotv Inc (FUBO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Moderna, Inc. — how do they compare? Fubotv Inc trades at $9.6 (market cap $1.06B), while Moderna, Inc. trades at $60.51 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 22.8× Fubotv Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| FUBO | MRNA | |
|---|---|---|
Market Cap | $1.06B | $24.18B |
Sector | Technology | Health |
52-Week High | $54.72 | $81.80 |
52-Week Low | $8.09 | $22.36 |
Enterprise Value | $1.23B | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.45, up 0.96% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q3 2026 revenue of $1.48 billion, beating expectations, and raised its full-year adjusted EBITDA outlook to $90–$100 million. Valuation ratios appear attractive with a P/E of 2.53 and P/S of 0.19, while recent leadership changes include the appointment of former Disney executive Alisa Bowen as CEO.
The outlook is positive as FUBO shows improving financials and strategic partnerships, but risks include persistent net losses and high debt. Analyst consensus is a Buy with a $15.33 price target, suggesting significant upside potential if profitability goals are met.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
